The first pivotal randomized clinical trial, TRILUMINATE, demonstrated that T-TEER can safely reduce TR and is associated with improved health status outcomes. However, results of this trial have raised questions about whether this device can provide sufficient TR reduction to impact clinical outcomes. Orthotopic TTVR has recently gained attention with initial data suggesting near-complete TR elimination. The current review examines the technical features and anatomic limitations of the most commonly used devices for T-TEER and orthotopic TTVR, discusses the current clinical data for these devices, and offers a theoretical construct for device selection.
Keyphrases
- aortic valve
- mitral valve
- aortic stenosis
- electronic health record
- transcatheter aortic valve replacement
- big data
- working memory
- study protocol
- randomized controlled trial
- clinical trial
- phase iii
- type diabetes
- ejection fraction
- left ventricular
- heart failure
- phase ii
- coronary artery disease
- skeletal muscle
- metabolic syndrome
- atrial fibrillation